文献速递慢性肾脏病水电解质与酸碱

碳酸氢盐治疗对肾脏结局影响的系统综述与荟萃分析

A Systematic Review and Meta-Analysis on Effects of Bicarbonate Therapy on Kidney Outcomes.
PubMed 文献 · Kidney Int Rep · 2020-12-31

结果显示碳酸氢钠可能延缓肾功能下降并降低终末期肾衰竭风险,但对蛋白尿、收缩压、全因死亡和水肿的影响不确定。

要点

  • 碳酸氢钠可能延缓CKD患者肾功能下降(SMD 0.26,低确定性证据)。
  • 碳酸氢钠可能降低终末期肾衰竭风险(RR 0.53,低确定性证据)。
  • 对蛋白尿、收缩压、全因死亡和水肿的影响不确定。

核心结论

  • 碳酸氢钠可能延缓CKD进展,但需要足够把握度的随机试验进一步评估其获益与风险。

研究设计与样本

  • 系统综述与荟萃分析,检索Medline、EMBASE和Cochrane数据库,纳入随访≥3个月的随机对照试验。
  • 纳入标准为CKD患者(eGFR≤60 ml/min per 1.73 m2和/或蛋白尿),比较碳酸氢钠与安慰剂/无研究药物。

主要发现

  • 与安慰剂或无研究药物相比,碳酸氢钠延缓肾功能下降(SMD 0.26;95%CI 0.13-0.40;I²=50%,低确定性证据)。
  • 碳酸氢钠降低终末期肾衰竭风险(RR 0.53;95%CI 0.32-0.89;I²=69%,低确定性证据)。
  • 对蛋白尿(SMD -0.09;95%CI -0.27至0.09;I²=28%,极低确定性证据)的影响不确定。
  • 对收缩压(WMD -0.57 mm Hg;95%CI -2.32至1.18;I²=0%,低确定性证据)的影响不确定。
  • 对全因死亡(RR 0.81;95%CI 0.39-1.68;I²=30%,极低确定性证据)和水肿(RR 1.16;95%CI 0.90-1.50;I²=28%,低确定性证据)的影响不确定。

临床怎么用

  • 对于合并代谢性酸中毒的CKD患者,碳酸氢钠可能作为延缓肾功能下降和降低终末期肾衰竭风险的策略。
  • 需注意证据确定性多为低或极低,临床决策应个体化并权衡潜在获益与风险。

局限性

  • 多数结局的证据确定性为低或极低,异质性中等(I²最高69%)。
  • 需要足够把握度的随机试验进一步验证。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

AIM: Preclinical studies suggest treatment of metabolic acidosis may slow chronic kidney disease (CKD) progression. This systematic review aimed to summarize evidence from randomized controlled trials (RCTs) concerning the benefits and risks of bicarbonate therapy on kidney outcomes. METHODS: Medline, EMBASE, and Cochrane databases were searched for RCTs with ≥3 months' follow-up in patients with CKD (estimated glomerular filtration rate [eGFR] ≤60 ml/min per 1.73 m2 and/or proteinuria) comparing the effects of sodium bicarbonate with placebo/no study medication on kidney outcomes. The primary outcome was change from baseline to last measurement in kidney function measured as either eGFR or creatinine clearance. Treatment effects were summarized using random-effects meta-analysis. RESULTS: Fifteen trials (2445 participants, median follow-up 12 months) were eligible for inclusion. Compared with placebo or no study medication, sodium bicarbonate retarded the decline in kidney function (standardized mean difference [SMD]: 0.26; 95% confidence interval [CI]: 0.13-0.40; I 2 = 50%, low certainty evidence), and reduced the risk of end-stage kidney failure (risk ratio [RR]: 0.53; 95% CI 0.32-0.89; I 2 = 69%, low certainty evidence). The effect of sodium bicarbonate on proteinuria (SMD: -0.09; 95% CI -0.27 to 0.09; I 2 = 28%, very low certainty evidence), systolic blood pressure (weighted mean difference [WMD]: -0.57 mm Hg; 95% CI -2.32 to 1.18; I 2 = 0%, low certainty evidence), all-cause death (RR: 0.81; 95% CI: 0.39-1.68; I 2 = 30%; very low certainty evidence) and edema (RR: 1.16; 95% CI: 0.90-1.50; I 2 = 28%; low certainty evidence) were uncertain. CONCLUSION: Sodium bicarbonate may slow CKD progression. Adequately powered randomized trials are required to evaluate the benefits and risks of sodium bicarbonate in CKD.

来源:Kidney Int Rep,查看原文。版权归原作者所有。

引用

  1. Hultin S, Hood C, Campbell KL, et al. A Systematic Review and Meta-Analysis on Effects of Bicarbonate Therapy on Kidney Outcomes. Kidney Int Rep. 2020. PMID: 33732984. doi:10.1016/j.ekir.2020.12.019

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。